Background: Thiazolopyrimidine analogues are versatile synthetic scaffold possessing wide spectrum of biological interests involving potential anticancer activity.

Objective: To report the synthesis of novel bromothiazolopyrimidine derivatives and the study of both molecular modeling and in-vitro anticancer activity.

Methods: Novel bromothiazolopyrimidine derivatives 5-18 have been prepared from 2-bromo-3-(4- chlorophenyl)-1-(3,4-dimethylphenyl)-propenone 3 as a key starting compound. The anti-cancer activities of the new compounds were evaluated against HepG2, MCF-7, A549 and HCT116 cell lines.

Results: The compounds 16, 17 and 18 showed cytotoxic and growth inhibitory activities on both colon and lung cells. The cytotoxic activities of the novel synthetic compounds 8, 9, 11, 16, 17 and 18 were due to CDC25 phosphatases inhibition as shown by the enzymatic binding assay. Although compounds 8, 9 and 11 have only demonstrated CDC25B phosphatases inhibition.

Conclusion: The novel bromothiazolopyrimidine derivatives showed promising in vitro anticancer activities against colon cancer HCT116 and lung cancer A549 cell lines comparable to the anticancer drug doxorubicin.

背景：噻唑并嘧啶类似物是通用的合成支架，具有广泛的生物学意义，涉及潜在的抗癌活性。

目的：报道新型溴噻唑并嘧啶衍生物的合成及其分子模型和体外抗癌活性的研究。

方法：由2-溴-3-（4-氯苯基）-1-（3,4-二甲基苯基）-丙烯酮3作为关键起始化合物制备了新的溴噻唑并嘧啶衍生物5-18。评估了新化合物对HepG2，MCF-7，A549和HCT116细胞系的抗癌活性。

结果：化合物16、17和18对结肠和肺细胞均显示出细胞毒性和生长抑制活性。如酶结合试验所示，新型合成化合物8、9、11、16、17和18的细胞毒性活性是由于CDC25磷酸酶抑制作用所致。尽管化合物8、9和11仅显示出CDC25B磷酸酶抑制作用。

结论：新型的溴噻唑并嘧啶衍生物显示出有希望的抗结肠癌HCT116和肺癌A549细胞系的体外抗癌活性，可与抗癌药阿霉素相比。